As of now, 24 laboratories in 11 states and two foreign countries are believed to have received suspect samples, the Pentagon said.» Read More
It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.
CNBC's Meg Tirrell, provides a preview of this weekend's meeting of the American Society of Clinical Oncology and which big pharma companies investors need to watch come Monday.
Michael Mussallem, Edwards Lifesciences CEO, provides insight into the future of treating heart disease.
Michael Mussallem, Edwards Lifesciences CEO, discusses major strides the medical community has made in cardiovascular treatment.
Pfizer reportedly approached Cellectis with a deal that could value it at about $1.64 billion, the Financial Times reported.
Some view skyrocketing biotech stocks as a bubble, but hedge funds are riding optimism in the sector to monster gains—for now.
A major drug prescription benefits manager is pushing to change the skyrocketing pricing structure, reports CNBC's Meg Tirrell
Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.
Cowen's David Seaburg has a very interesting way to play biotech and pharma stocks now.
In the world's fight against antibiotic resistance, Bayer CEO Marijn Dekkers sees the need for a global antibiotics bailout.
A federal appeals court has made a ruling on a top selling Alzheimer's drug that could make things difficult for drugmaker Actavis, reports CNBC's Meg Tirrell.
Mark Cuban said innovative tech in the pharmaceutical sector is going to be a game changer not only for health care, but for humanity.
Cheaper biotech drugs are headed to the U.S., but analyst Mike Weinstein thinks J&J can manage through some of the challenges.
Michael Weinstein, JPM, managing director of healthcare, joins CNBC's Meg Tirrell to discuss biosimilar, the threat to big pharmaceuticals, and how Johnson & Johnson will be affected.
Researchers at UC Irvine restored a key feature of young brains, the flexibility that allows for learning and creativity.
"You're going to have some wins and some that don't turn out," J&J chief Alex Gorsky tells CNBC. "But overall we're very confident."
The New England Compounding Center sickened about 750 people and killed at least 64 across the United States three years ago.
Jeffrey Marrazzo, Spark Therapeutics CEO, and Dr. Jean Bennett, Spark Therapeutics advisor, discuss how advances in gene therapy are changing the way rare diseases are treated. And Gordon Gund, Gund Investment Corp. CEO, weighs in.
"This will position us as a top-five generics player in the U.S.," Endo International CEO Rajiv De Silva says.
CNBC's Meg Tirrell breaks down all the biotech data coming out ahead of the ASCO Conference, and why Clovis Oncology's stock is climbing.
Get the best of CNBC in your inbox